Ftse Mib
36.059,17
0,00%
DAX
21.041,52
0,00%
S&P 500
6.049,24
0,88%
NASDAQ
19.756,78
0,64%
Bitcoin
105.141,03
-0,97%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Citius Pharmaceuticals Inc (CTXR) Citius Pharmaceuticals Inc (CTXR) Notizie

Citius Pharmaceuticals Inc

CTXR
3,20
-0,10 (-3,03%)
22 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/1/202522:30EDGAR2Form PRE 14A - Other preliminary proxy statements
08/1/202522:05EDGAR2Form 8-K - Current report
08/1/202515:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/1/202514:00PRNUSCitius Pharmaceuticals Announces $3 Million Registered..
07/1/202515:11EDGAR2Form 8-K - Current report
07/1/202514:08PRNUSCitius Pharmaceuticals and Citius Oncology Highlight LYMPHIR..
06/1/202513:50PRNUSCitius Oncology Engages Jefferies as Exclusive Financial..
27/12/202423:10EDGAR2Form 8-K - Current report
27/12/202423:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/12/202423:00PRNUSCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024..
20/12/202422:30EDGAR2Form 8-K - Current report
26/11/202422:15EDGAR2Form 8-K - Current report
25/11/202423:15EDGAR2Form 8-K - Current report
25/11/202414:03PRNUSCitius Pharmaceuticals Reports Productive FDA Type C Meeting..
22/11/202415:00PRNUSCitius Pharmaceuticals, Inc. Announces 1-for-25 Reverse..
18/11/202422:15EDGAR2Form 8-K - Current report
18/11/202422:05PRNUSCitius Pharmaceuticals Announces Closing of $3 Million..
18/11/202414:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/11/202419:30PRNUSCitius Pharmaceuticals Announces $3 Million Registered..
13/11/202422:30EDGAR2Form 8-K - Current report
12/11/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/11/202414:45PRNUSCitius Pharmaceuticals, Inc. and Citius Oncology, Inc...
27/9/202423:25EDGAR2Form 8-K - Current report
13/9/202414:30EDGAR2Form 8-K - Current report
11/9/202423:26EDGAR2Form 8-K - Current report
05/9/202422:30PRNUSCitius Pharmaceuticals to Participate in the H.C. Wainwright..
05/9/202422:15EDGAR2Form 8-K - Current report
05/9/202414:30PRNUSCitius Pharmaceuticals, Inc. and Citius Oncology, Inc...
30/8/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202422:35EDGAR2Form 8-K - Current report
16/8/202422:34EDGAR2Form SC 13D - General Statement of Acquisition of Beneficial..
15/8/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202400:19EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/8/202423:28PRNUSCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter..
12/8/202423:25EDGAR2Form 8-K - Current report
12/8/202423:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/8/202422:51EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/8/202422:22PRNUSCitius Pharmaceuticals Completes Merger of Subsidiary with..
12/8/202414:00PRNUSCitius Pharmaceuticals to Host Investor Call to Discuss..
09/8/202413:30GLOBETenX Keane Acquisition Addresses Trading Halt, Continues..
08/8/202415:20EDGAR2Form 8-K - Current report
08/8/202412:59PRNUSCitius Pharmaceuticals Receives FDA Approval for LYMPHIR™..
05/8/202414:00PRNUSCitius Pharmaceuticals Announces TenX Keane Shareholder..
10/7/202415:10PRNUSCitius Pharmaceuticals Details Near-Term Milestones for..
Apertura: 3,25 Min: 3,14 Max: 3,29
Chiusura: 3,30

La tua Cronologia

NASDAQ
CTXR
Citius Pharmaceuticals
LSE
0QQZ
St Galler Kantonalbank
USOTC
UVSS
Universal Systems Inc Wa... (CE)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network